title: factors influencing mucosal healing in Crohn's disease during infliximab treatment.
abstract: OBJECTIVE
  The effect of infliximab (IFX) on mucosal healing (MH) in clinical setting, as well as what is the effect of scaring of profound ulcers on bowel, is not well known. Aim of our study was to assess how MH occurs in Crohn's disease (CD) in clinical setting during treatment with IFX.
  
  
  METHODS
  Forty patients with CD were followed-up. MH and endoscopic remission (ER) were assessed. Some factors were investigated in predicting development of "uncomplicated" (ulcer healing without alteration of bowel profile) or "complicated" (ulcer healing with alteration of bowel profile) MH.
  
  
  RESULTS
  IFX was administered for a mean of 36 months. MH ranged from 67.5% of cases after 6 months to 42.5% of cases after 3 year of treatment. ER ranged from 87.5% of cases after 6 months to 52.5% of cases after 3 year of treatment. Mean CDEIS score decreased from 28 to 8 at the end of follow-up. Uncomplicated MH occurs in 70.37% of patients, complicated MH occurred in 29.63% of patients. Complicated MH was recorded more frequently in patients with severe CDAI (>300 vs. <300, p <0.0362) and higher CDEIS (>35 vs. <35, p >0.0342).
  
  
  CONCLUSIONS
  Complicated MH seems to occur frequently in clinical practice when using IFX, especially in patients with higher indexes of activity at entry.
authors.forename: Antonio
authors.initials: A
authors.lastname: Tursi
authors.forename: Walter
authors.initials: W
authors.lastname: Elisei
authors.forename: Gian Marco
authors.initials: GM
authors.lastname: Giorgetti
authors.forename: Antonio
authors.initials: A
authors.lastname: Penna
authors.forename: Marcello
authors.initials: M
authors.lastname: Picchio
authors.forename: Giovanni
authors.initials: G
authors.lastname: Brandimarte
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab